
NEW YORK, May 24 (Reuters) - Small- and midcapitalization stocks edged higher on Thursday, with shares of Synopsys Inc and other companies up after they raised their outlooks for the year.
* Sees FY12 adj EPS $2.03-$2.07 vs prev. view $1.97-$2.03
Synopsys ( SNPS ): FQ2 EPS of $0.53 misses by $0.02 . Revenue of $432M (+9.9% Y/Y) beats by $15M . Shares -0.1% AH. ( PR ) Post your comment!
Synopsys SNPS reported robust second-quarter results ..... our fair value estimate for the firm. Synopsys generated $432.5 million in revenues ..... quarter and $394 million a year ago. Synopsys benefited from strong demand for IP code
and gentlemen, thank you for standing by. Welcome to the Synopsys Earnings Conference Call for the Second Quarter Fiscal Year ..... the call today are Aart de Geus, Chairman and co-CEO of Synopsys and Brian Beattie, Chief Financial Officer. Click here for
Notable earnings after Wednesday's close: HPQ , NTAP , P , PVH , SNPS , SPLK Post your comment!
BREVAGen breast cancer test. BREVAGen offers unique preliminary DNA testing for the presence of single nucleotide polymorphisms ( SNPs ) which increase the likelihood of a woman developing breast cancer. The microcap company was up some 30% as of press time
offerings competitive with rivals like Synopsys . Cadence Design is a leader in ..... losses. Cadence's competitor, Synopsys SNPS , was the chief beneficiary of the firm's struggles, and Synopsys now has an advantage in market
positioned in adjacent industries to outgrow the EDA market and has a first-mover advantage over its larger competitors, Synopsys SNPS and Cadence CDNS. Mentor increased its exposure to fluid dynamics systems with its December acquisition of Flowmaster
major competitors, Cadence and Synopsys , have superior economies of scale ..... upfront, while both Cadence and Synopsys have moved to recognize revenues ..... Cadence Design Systems CDNS and Synopsys SNPS . Both firms have broader product